Institutes outside Greece
Charakterisierung von Retinoblastomen mit Amplifikation des Onkogens MYCN
Abstract
dc:descriptionAmplification of the oncogene MYCN has been described in a minority of retinoblastomas with and without RB1 inactivation. It is assumed that MYCN amplified retinoblastomas are associated with a more aggressive clinical behavior and an unfavorable prognosis. In this dissertation, the incidence, RB1 mutational status, clinical phenotype and histopathologic features of MYCN amplified retinoblastoma were investigated. For this purpose, MYCN copy number was determined by qPCR in a series of 192 tumors of enucleated retinoblastoma patients and confirmed by SNP array and FISH studies. Subsequently, clinical characteristics, RB1 genotype and histopathological features were compared between MYCN amplified tumors (MYCN-A) and tumors without MYCN amplification (MYCN-nichtA).Overall, MYCN amplification was detected in 10/139 (7%) of the tumors included in the final dataset. All MYCN amplified tumors showed pathogenic alterations in at least one RB1 allele as well as other aberrations characteristic for retinoblastoma. Age at diagnosis was similar for patients in the MYCN-A and MYCN-nichtA group. However, striking differences were found when comparing the distribution of clinical and histopathologic risk factors (HRPFs) between the two groups: The children in the MYCN-A group were significantly more likely to have secondary glaucoma at initial diagnosis as well as massive choroidal and scleral infiltration. The examination of the remaining histopathological high risk factors (optic nerve infiltration and anterior chamber involvement) also showed a non-statistically significant trend in the same direction. In addition, increased expression of TFF1, a surrogate marker for advanced tumor stage associated with a poor prognosis, was observed in 7/8 (88%) MYCN amplified retinoblastomas. Nevertheless, none of the patients included in the study developed extraocular relapse or distant metastases.The results of this work support the hypothesis that MYCN amplified retinoblastomas show distinct aggressive clinical and histopathological characteristics. However, the rarity of MYCN amplified retinoblastoma and the small number of cases included in this study do not allow generalisation of these findings. Further multicentre, prospective studies are needed in the future to better characterise this subgroup of tumors and to validate the value of MYCN amplification as a genetic tumor marker for therapy control and prognosis assessment in retinoblastoma patients.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papaioannou, Kyriaki
- Παπαϊωάννου, Κυριακή
Subjects
dc:subject × 30- Ρετινοβλάστωμα
- Ογκογονίδιο ΜYCN
- Βιοδείκτες
- Χημειοθεραπεία συστηματική
- Πρόγνωση
- Διήθηση
- Γλαύκωμα
- Retinoblastoma
- Oncogene MYCN
- Biomarkers
- Systemic chemotherapy
- Enucleation
- Prognosis
- Infiltration
- Glaucoma
- Retinoblastom
- Onkogen MYCN
- Biomarker
- Systemische Chemotherapie
- Enukleation
- Prognose
- Glaukom
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Παιδιατρική, Νεογνολογία και Υγεία του παιδιού
- Clinical Medicine
- Medical and Health Sciences
- Oncology
- Pediatrics, Perinatology and Child Health
Rights
- Language dc:language
- ger
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62565